

## PRESS CLIPPING SHEET

<b>PUBLICATION:</b>	Daily News
<b>DATE:</b>	06-December-2018
<b>COUNTRY:</b>	Egypt
<b>CIRCULATION:</b>	80,000
<b>TITLE :</b>	Bayer Group adopts structural measures to strengthen core life science business.
<b>PAGE:</b>	06
<b>ARTICLE TYPE:</b>	Agency Generated News
<b>REPORTER:</b>	Staff Report
<b>AVE:</b>	13,020

### **Bayer Group adopts structural measures to strengthen core life science business**

The Bayer Group aims to strengthen its core life science businesses through a series of portfolio, efficiency and structural measures designed to enhance productivity and innovation, while significantly improving competitiveness. In a meeting, the supervisory board of Bayer AG discussed the plans laid out by the board of management and unanimously expressed their support. Through these measures, the company is paving the way for sustainable business success in attractive, long-term growth markets. "We have made very good progress with Bayer's strategic development in recent years. As we now proceed with these measures, we are laying the foundation to sustainably enhance Bayer's performance and profitability," said Werner Baumann, chairperson of the board of management of Bayer AG. "With these measures, we are positioning Bayer optimally for the future as a life science company."

Bayer intends to advance the portfolio measures in 2019. The company intends to exit the Animal Health

business, and is assessing available options. Although this unit offers growth options in an attractive market, Bayer intends to allocate the investment resources necessary to support Animal Health to Bayer's core businesses of Pharmaceuticals, Consumer Health, and Crop Science.

At Consumer Health, the company has initiated measures to enable the division to catch up to market growth in the coming years, and improve profitability. These measures include a planned exit from product categories which have more favourable development potential outside of Bayer. In addition to the previously announced divestment of prescription dermatology products, Bayer will review its strategic options in the coming months, with a view to exiting the sun care (Coppertone) and foot care (Dr. Scholl's) product lines. Through these moves, the company intends to focus on driving profitable growth into its core Consumer Health categories.